 |
| A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Eli Lilly and Company | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |
| A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of LY3526318 in Healthy Male Japanese Participants | Eli Lilly and Company | NA |
WITHDRAWN
(Sep 1, 2026)
| PHASE1 |
| A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study of Brenipatide in Participants With Alcohol Use Disorder | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Brenipatide in Participants With Opioid Use Disorder | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study of LY4355756 in Healthy Participants | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight | Eli Lilly and Company | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation | Eli Lilly and Company | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Eli Lilly and Company | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Abemaciclib (LY2835219) in Healthy Participants | Eli Lilly and Company | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | Eli Lilly and Company | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Eli Lilly and Company | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Eli Lilly and Company | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2, PHASE3 |
| A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis | Eli Lilly and Company | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | Eli Lilly and Company | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1, PHASE2 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE1 |
| Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | Eli Lilly and Company | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |
| A Study of Baricitinib (LY3009104) in Children With COVID-19 | Eli Lilly and Company | NA |
TERMINATED
(Jul 1, 2026)
| PHASE3 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Eli Lilly and Company | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Eli Lilly and Company | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Study of LY4515100 in Healthy Participants | Eli Lilly and Company | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1 |
| A Study of LY3502970 in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1 |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE1 |
| A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1 |
| A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Eli Lilly and Company | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| A Study of LY4175408 in Participants With Advanced Cancer | Eli Lilly and Company | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1 |
| A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Eli Lilly and Company | NA |
COMPLETED
(May 1, 2026)
| PHASE2 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Eli Lilly and Company | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE2 |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |
| A Study of Olomorasib (LY3537982) in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |
| A Multiple Dose Study of LY3502970 in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Apr 15, 2026)
| PHASE1 |
| A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Apr 15, 2026)
| PHASE1 |
| Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |
| A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |
| A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |
| A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants | Eli Lilly and Company | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |
| A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants | Eli Lilly and Company | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE2 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE1, PHASE2 |
| A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata | Eli Lilly and Company | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2, PHASE3 |
| A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata | Eli Lilly and Company | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |
| A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |
| A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Eli Lilly and Company | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Eli Lilly and Company | NA |
RECRUITING
(Sep, 2024)
| PHASE2 |
| A Study of LY3841136 in Overweight and Obese Participants | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Sep, 2024)
| PHASE1 |
| A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | Eli Lilly and Company | NA |
COMPLETED
(Aug, 2024)
| PHASE4 |
| A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Eli Lilly and Company |
Regeneron Pharmaceuticals
|
RECRUITING
(Aug, 2024)
| PHASE2 |
| A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Eli Lilly and Company | NA |
COMPLETED
(Jul, 2024)
| PHASE3 |
| A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Eli Lilly and Company | NA |
ACTIVE NOT RECRUITING
(Jul, 2024)
| PHASE3 |
| A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Eli Lilly and Company | NA |
COMPLETED
(Apr, 2024)
| PHASE2 |
| A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes | Eli Lilly and Company | NA |
COMPLETED
(Jun, 2022)
| PHASE1 |
| A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Eli Lilly and Company | NA |
COMPLETED
(Jan, 2022)
| PHASE3 |
